Anti-Lymphocyte Activation Gene 3 Antibody, Non-Fucosylated (BioBet-1162ZP) (CAT#: BioBet-1162ZP) Datasheet

LAG3

lymphocyte-activation gene 3

Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4.

LAG3; lymphocyte-activation gene 3; CD223; lymphocyte activation gene 3 protein

Plasma membrane, Extracellular region or secreted

Diseases associated with LAG3 include Smoldering Myeloma and Kyphoscoliotic Heart Disease.

Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.

Lymphocyte activating gene 3 protein: an inhibitory receptor for antigen activated T cells. When binding to ligands, it transmits inhibitory signals, such as FGL1 (via similarity). The ligand GL3 is responsible for the inhibition of gfg3. After TCR involvement, Lag3 binds to cd3-tcr at immune synapses, directly inhibiting T cell activation (through similarity). Cdpd-1 may act as a synergetic antigen of cdpd-1. It negatively regulates the proliferation, activation, effector function and homeostasis of CD8 (+) and CD4 (+) T cells. It also mediates immune tolerance: constitutes regulatory T cells (Tregs) expressed in a subset and contributes to their inhibitory function (through similarity). It also acts as a negative regulator of plasma cell like dendritic cells (pDCs) activation (through similarity). However, the exact role of MHC - II binding is still unclear.

1.[Lymphocyte activation gene 3 protein]: Proteolytically cleaved by ADAM10 and ADAM17 within the connecting peptide region, leading to release of Secreted lymphocyte activation gene 3 protein (sLAG-3). ADAM10 mediates constitutive cleavage, but cleavage increases following T-cell activation, whereas shedding by ADAM17 is induced by TCR signaling in a PRKCQ-dependent manner. 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn188, Asn250, Asn256, and Asn343

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-1162ZP

Humanized

Human

GSK2831781 is a monoclonal antibody being developed for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. GSK2831781 entered a Phase I clinical trial in psoriasis early in 2015.

Plaque psoriasis

Plaque psoriasis